Karyopharm Therapeutics Inc.

Form 4 July 25, 2014

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Plio Ltd Issuer Symbol Karyopharm Therapeutics Inc. (Check all applicable) [KPTI] \_X\_\_ 10% Owner (Last) (First) (Middle) 3. Date of Earliest Transaction Director \_X\_ Other (specify Officer (give title (Month/Day/Year) below) below) SIMOU MENARDOU 8,, RIA 07/23/2014 Former 10% Owner (exit filing) COURT 8, OFFICE 101 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting 6015 LARNACA, G4 Person

(City)	(State) (Z	Zip) Table	e I - Non-D	erivative Se	curitie	es Acquired,	, Disposed of, or	Beneficially	Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securitie or Disposed of (Instr. 3, 4)  Amount	f (D)	uired (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
COMMON STOCK	07/23/2014		S	500,000	A	\$ 35.5437	2,693,473 <sub>(1)</sub>	$D_{(3)} \frac{(1)}{(2)}$	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

9. Nu Deriv Secur Bene Own

Follo Repo Trans (Instr

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Title a	and	8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transac	tionNumber	Expiration D	ate	Amount	of	Derivative
Security	or Exercise		any	Code	of	(Month/Day/	/Year)	Underly	ing	Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8	) Derivativ	re		Securitie	es	(Instr. 5)
	Derivative				Securities	S		(Instr. 3	and 4)	
	Security				Acquired			`		
	•				(A) or					
					Disposed					
					of (D)					
					(Instr. 3,					
					4, and 5)					
					.,					
								A	mount	
						Date	Expiration	01	r	
						Exercisable Date	Title N	Title Number		
							Date	О	f	
				Code	V (A) (D)			Sl	hares	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Plio Ltd SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X		Former 10% Owner (exit filing)				
Czernik Marcin SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X						
Hadjimichael Andreas SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X						
Hadjimichael Amalia SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X						
Jankilevitsch Gregory CHALET LE REFUGE CHEMIN DE JOLIMONT 18 VILLARS-SUR-OLLON, V8 CH-1884				Former 10% Owner (exit filing)				
Cianaturas								

## **Signatures**

/s/ Plio Limited, by /s/ Simon Prisk, as attorney-in fact by power of attorney				
**Signature of Reporting Person	Date			
/s/ Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney				
**Signature of Reporting Person	Date			
	07/25/2014			

Reporting Owners 2

#### Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

/s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

> \*\*Signature of Reporting Person Date

/s/ Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of 07/25/2014 attorney

\*\*Signature of Reporting Person

Date

/s/ Gregory Jankilevitsch, by /s/ Simon Prisk, as attorney-in fact by power of attorney

07/25/2014

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Shares of Common Stock are owned directly by Plio Limited ("Plio"). Plio's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. Gregory Jankilevitsch, the sole shareholder of Plio, may also be deemed to share voting and investment power
- **(1)** and beneficial ownership of the shares of Common Stock directly owned by Plio. The shares owned by Plio do not include the 10,258,079 shares of the issuer's Common Stock held by Chione Limited, which has the same directors as Plio.
- Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any **(2)** securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
- Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be **(3)** construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

#### **Remarks:**

Exhibit Index Exhibit 24.1 - Power of Attorney, dated November 5. 2013, made by Marcin Czernik and Plio Limited in favor

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3